potential partners in the biosphere, page-4

I don't think they know anything, just likely day traders. Only $25 k today. I think there will be a lot of people kicking themselves in the not too distant future. I recommend all battle scarred shareholders read an extract from Professor Richard Bond titled 'Ligand bias prevents class equality among beta blockers'. It explains why only Nadolol and ICI ( an old toxic compound) are the only 2 drugs that effectively block the beta arrestin pathway. Other beta blockers and inverse agonist beta blockers are ineffective when treating asthma. So Nadolol has a proven safety record, proven mechanism of action following successful phase 2 trials, is first in class, targets mega markets of asthma, copd, smoking cessation, cystic fibrosis, the science is derived from 2012 Nobel prize winner, developed by industry doyens Prof Bond/ Dr Mitchell Glass, and it has no competition - other beta blockers don't work. Market cap 7 million. Common.